Wockhardt Limited, the pharmaceutical and biotechnology major, has reported a significant turnaround in its financial performance for the fiscal year 2025-26. The company achieved a profit before tax (PBT) of ₹238 crore for FY26, a substantial improvement from a loss of ₹16 crore in the previous year.
For the fourth quarter of FY26, Wockhardt recorded a PBT of ₹189 crore, compared to a loss of ₹22 crore in the same quarter of the previous year. The company’s revenue for Q4FY26 grew by 30% to ₹965 crore, up from ₹743 crore in the previous year. The EBITDA for the quarter also saw a remarkable increase of 147%, reaching ₹196 crore as opposed to ₹79 crore in the prior year.
On an annual basis, Wockhardt’s revenue for FY26 rose by 11% to ₹3,373 crore, compared to ₹3,033 crore in FY25. The EBITDA for the year increased by 51%, amounting to ₹630 crore compared to ₹418 crore in the previous year.
Wockhardt’s biosimilar segment also demonstrated robust growth. The biotech operations for Q4FY26 stood at ₹252 crore, marking a 126% increase over Q4FY25. For the full fiscal year, the biotech operations recorded a 27% growth, delivering ₹697 crore. This growth was driven by strategic business partnerships and new deal acquisitions in key markets such as Thailand, Egypt, Algeria, and LATAM.
Region-wise, the India Branded Business reported a revenue of ₹112 crore in Q4FY26, an 18% increase compared to the previous year. For FY26, the business grew by 15% to ₹523 crore. The UK region achieved a revenue of ₹349 crore in Q4FY26, a 20% growth from the previous year, while the Emerging Markets region reported ₹320 crore, a 124% increase.
Wockhardt’s strategic focus on expanding its biotech infrastructure and the upcoming launch of insulin analogues are expected to further strengthen its position in the global diabetes care market.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).